Calithera Biosciences, Inc. (CALA) Analysts See $-0.24 EPS

February 15, 2018 - By Darrin Black

 Calithera Biosciences, Inc. (CALA) Analysts See $ 0.24 EPS
Investors sentiment decreased to 1.22 in Q3 2017. Its down 2.03, from 3.25 in 2017Q2. It dropped, as 16 investors sold Calithera Biosciences, Inc. shares while 21 reduced holdings. 14 funds opened positions while 31 raised stakes. 25.24 million shares or 49.47% less from 49.95 million shares in 2017Q2 were reported.
Artal Group Sa holds 0.05% of its portfolio in Calithera Biosciences, Inc. (NASDAQ:CALA) for 175,000 shares. The California-based Clarivest Asset Management Ltd Liability Corporation has invested 0.02% in Calithera Biosciences, Inc. (NASDAQ:CALA). State Common Retirement Fund owns 32,700 shares. Manufacturers Life Insur The owns 24,027 shares for 0% of their portfolio. Moreover, Blackrock has 0% invested in Calithera Biosciences, Inc. (NASDAQ:CALA) for 2.10 million shares. First Personal Fin Svcs has 1,359 shares for 0% of their portfolio. Victory Capital Management, a Ohio-based fund reported 97,280 shares. Pacad Investment Ltd has 10,000 shares for 0.03% of their portfolio. Wellington Management Grp Limited Liability Partnership invested in 4.68M shares. Meeder Asset Mngmt reported 52 shares. Barclays Public reported 0% stake. Millennium Management Lc stated it has 482,136 shares or 0.01% of all its holdings. Jacobs Levy Equity reported 18,565 shares. Trexquant L P owns 10,676 shares or 0.04% of their US portfolio. Teachers Retirement Systems Of The State Of Kentucky owns 27,600 shares.

Analysts expect Calithera Biosciences, Inc. (NASDAQ:CALA) to report $-0.24 EPS on March, 15.They anticipate $0.21 EPS change or 46.67 % from last quarter’s $-0.45 EPS. After having $-0.17 EPS previously, Calithera Biosciences, Inc.’s analysts see 41.18 % EPS growth. The stock decreased 1.41% or $0.1 during the last trading session, reaching $7. About 256,369 shares traded. Calithera Biosciences, Inc. (NASDAQ:CALA) has risen 278.82% since February 15, 2017 and is uptrending. It has outperformed by 262.12% the S&P500.

Calithera Biosciences, Inc. (NASDAQ:CALA) Ratings Coverage

Among 5 analysts covering Calithera Biosciences (NASDAQ:CALA), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Calithera Biosciences had 9 analyst reports since July 24, 2015 according to SRatingsIntel. The company was maintained on Monday, June 12 by H.C. Wainwright. As per Friday, July 24, the company rating was initiated by Citigroup. The rating was maintained by JMP Securities on Wednesday, March 9 with “Market Outperform”. As per Tuesday, March 28, the company rating was maintained by H.C. Wainwright. H.C. Wainwright initiated the shares of CALA in report on Thursday, January 5 with “Buy” rating. The firm has “Sell” rating given on Tuesday, October 25 by Citigroup. Citigroup upgraded Calithera Biosciences, Inc. (NASDAQ:CALA) on Tuesday, January 24 to “Neutral” rating.

Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company has market cap of $248.34 million. The Company’s lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase Ib/2 clinical trials for the treatment of solid tumors. It currently has negative earnings. The firm has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare; and license and research agreement with High Point Pharmaceuticals, LLC and TransTech Pharma LLC to develop and commercialize hexokinase II inhibitors.

Another recent and important Calithera Biosciences, Inc. (NASDAQ:CALA) news was published by Streetinsider.com which published an article titled: “Form SC 13G/A Calithera Biosciences, Filed by: VIKING GLOBAL INVESTORS LP” on February 14, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: